Check out our COVID-19 dedicated page for tenders related to medical equipment needs.
231901-2021 - Belgium-Brussels: Production, Priority-purchasing Options and Supply of Covid-19 Vaccines, Including Adapted Vaccines to SARS-CoV-2 Variants and Paediatric Formulations of such Vaccines for EU Member States
Spain-Barcelona: Research and experimental development services
Prior information notice
This notice is for prior information only
Section I: Contracting authority
Section II: Object
Pre–commercial procurement to buy R&D services for the development of early- and continuous-detection systems of microorganisms that may lead to hospital-acquired infections.
This prior information notice announces an open market consultation and provides information at an early stage on the expected starting date and purchase volume for the ANTI-SUPERBUGS PCP pre-commercial procurement.
The ANTI-SUPERBUGS pre-commercial procurement aims to improve the quality of care processes in hospital and the reduction of both the costs and the collateral effects provoked by Multi-Drug Resistant Organisms (MDROs, otherwise known as Superbugs) and other Health Associated Infections (HAIs) pathogens, through the development and testing of prototypes of devices and ICT services that can:
(1) test non-invasively for the presence of MDROs and other pathogens, and
(2) provide continuous information and remote alerts to health professionals on environmental contamination by MDROs — and other pathogens — on high contact surfaces, applicable to existing healthcare environments.
Main site or place of performance: R&D services to be developed will be integrated with resources in centres operated by buyers group.
This procurement receives funding from the European Commission Horizon 2020 Research and Innovation Programme (H2020-EU.2.1.1.- Industrial Leadership — Leadership in enabling and industrial technologies — Information and Communication Technologies (ICT)) Grant Agreement No. 688878. The EU is however not participating as a contracting authority in this procurement.
The procurement will be carried out jointly by the organisations of the buyers' group, and the Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) will act as lead procurer and will award the contracts on behalf of the buyers group.
As of the date of the publication of this information notice ANTI-SUPERBUGS PCP buyers' group members are:
— Institut Catala D'oncologia (Spain)
— Universitaetsklinikum Aachen (Germany)
— Sheffield Teaching Hospitals Nhs Foundation Trust (United Kingdom)
— Provincia Autonoma Di Trento (Italy)
The Anti-superbugs PCP buyers' group may be subject to variations as it is currently accessioning new contracting authorities.
The aim of this procurement is to trigger new solutions to be developed and tested to address the described common challenge faced by all buyers' group organizations. ANTI-SUPERBUGS PCP challenges the market to develop solutions that when in contact with resistant microorganisms can detect their presence and give real-time feedback to the user, and at the same time share the information with the healthcare provider ICT systems, linking the infection with the place of the detection.
The procurement will take the form of an open PCP under which R&D service contracts will be awarded to a number of R&D providers, in parallel, in a three-phase approach.
The three phases are:
1 Solution design
3 Original development and validation & testing of a limited set of prototype devices or prototype services within the contracting authorities.
After each phase, intermediate evaluations will be carried out to progressively select the best of the competing solutions. The contractors with the best value-for-money solutions will be offered a specific contract for the next phase.
The procurement is expected to start by Mid-2018 and end by 2020.
The total estimated budget of the PCP will be of approximately 4 000 000 EUR (including VAT).
Open Market Consultation: In preparation for this PCP, all interested operators are invited to take part in an open market consultation. The open market consultation will provide an overview on the procurement objectives, the PCP process and the main clauses of the contract. It will be also an opportunity to pose questions to the procuring authorities.
The market consultation involves the proactive analysis of technology offerings and provides pre-information to the market in order to give adequate time for the preparation of fit-for-purpose proposals. The market consultation will provide crucial input to the procurement plan. The market consultation aims to:
— find out whether technologies are commercially available and acquire information about the advantages and disadvantages and the level of fulfilment of the desired functionalities;
— identify market risks that may endanger business goals and supplier performance;
— enable and increase the opportunities for industry to form fit-for-purpose consortia.
The open market consultation will be held at least in English in the form of:
— open events (the registration to the events will be made available at the project website http://www.antisuperbugs.eu); such as one on 15.12.2017 at AQuAS (Barcelona), on January 18th, 2018 at Improving Infection Control within Healthcare conference, University of Salford,(Manchester), on 24.1.2018 at ZENIT Headquarters (Germany), on January 31st, 2018 at the Province of Trento (Italy), &
— a questionnaire
All information regarding the open market consultation and the information provided during the consultation will be published on website (http://www.antisuperbugs.eu)
Participation in the open market consultation will not be a requirement to submit a proposal to the tender, does not lead to any rights or privileges for the participants, and is not part of any pre-qualification or selection process.
— Project website (http://www.antisuperbugs.eu)
— Section on PCP on the EC website https://ec.europa.eu/digital-single-market/en/innovation-procurement
Section IV: Procedure
Section VI: Complementary information
According to the Annex E. Specific requirements for innovation procurement (PCP/PPI) supported by Horizon 2020 grants of the HORIZON 2020 — Work Programme 2014-2015:
‘The PCP only covers the procurement of R&D services, in a way that is clearly separated from any potential subsequent purchases of commercial volumes of end-products. Procurers undertaking a PCP can if they so desire, but are not obliged to, after the PCP procure at market price R&D results generated during a PCP (...). The PCP contract that will be concluded with each selected tenderer shall take the form of one single framework agreement covering all PCP phases, which does not involve contract renegotiations after contract award. This framework agreement shall contain information on the future procedure for implementing the different phases (through specific contracts), including the format of the intermediate evaluations (incl. evaluation criteria and weightings) after the solution design and prototype development phases’
This PIN is published to announce an open market consultation on potential future procurement activity and is not a commitment to procure. It doesn't oblige the contracting authority to set limits to the content of the invitation to tender.
The PCP procurement is exempted from the WTO Government Procurement Agreement (GPA), the EU public procurement directives and the national laws that implement them. This is because it concerns the procurement of R&D services where the benefits do not accrue exclusively to the contracting authorities for its use in the conduct of their own affairs.